These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 9094143)
1. Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions. Wan RQ; Corbett R Neuropsychopharmacology; 1997 Apr; 16(4):259-68. PubMed ID: 9094143 [TBL] [Abstract][Full Text] [Related]
2. Hippocampal modulation of locomotor activity induced by focal activation of postsynaptic dopamine receptors in the core of the nucleus accumbens. Rouillon C; Abraini JH; David HN Hippocampus; 2007; 17(11):1028-36. PubMed ID: 17604350 [TBL] [Abstract][Full Text] [Related]
3. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. Neal-Beliveau BS; Joyce JN Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220 [TBL] [Abstract][Full Text] [Related]
4. Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis studies. Wan RQ; Giovanni A; Kafka SH; Corbett R Behav Brain Res; 1996 Aug; 78(2):211-23. PubMed ID: 8864054 [TBL] [Abstract][Full Text] [Related]
5. Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats. Moro H; Sato H; Ida I; Oshima A; Sakurai N; Shihara N; Horikawa Y; Mikuni M Pharmacol Biochem Behav; 2007 May; 87(1):56-64. PubMed ID: 17499349 [TBL] [Abstract][Full Text] [Related]
6. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. Ralph RJ; Caine SB J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551 [TBL] [Abstract][Full Text] [Related]
7. Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpirole. Hooks MS; Jones DN; Holtzman SG; Juncos JL; Kalivas PW; Justice JB Psychopharmacology (Berl); 1994 Oct; 116(2):217-25. PubMed ID: 7862951 [TBL] [Abstract][Full Text] [Related]
8. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. Flores G; Wood GK; Liang JJ; Quirion R; Srivastava LK J Neurosci; 1996 Nov; 16(22):7366-75. PubMed ID: 8929443 [TBL] [Abstract][Full Text] [Related]
9. Studies on electroencephalogram (EEG) in rats suggest that moderate doses of cocaine or d-amphetamine activate D1 rather than D2 receptors. Ferger B; Kropf W; Kuschinsky K Psychopharmacology (Berl); 1994 Mar; 114(2):297-308. PubMed ID: 7838923 [TBL] [Abstract][Full Text] [Related]
10. The role of D1 and D2 receptors in the heightened locomotion induced by direct and indirect dopamine agonists in rats with hippocampal damage: an animal analogue of schizophrenia. Mittleman G; LeDuc PA; Whishaw IQ Behav Brain Res; 1993 Jun; 55(2):253-67. PubMed ID: 8102851 [TBL] [Abstract][Full Text] [Related]
11. Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats. Wilkerson A; Levin ED Neuroscience; 1999 Mar; 89(3):743-9. PubMed ID: 10199609 [TBL] [Abstract][Full Text] [Related]
12. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates. Byrnes EM; Bruno JP Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729 [TBL] [Abstract][Full Text] [Related]
13. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Zhou LW; Qin ZH; Weiss B Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors. Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972 [TBL] [Abstract][Full Text] [Related]
17. Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Wood GK; Lipska BK; Weinberger DR Brain Res Dev Brain Res; 1997 Jul; 101(1-2):17-25. PubMed ID: 9263576 [TBL] [Abstract][Full Text] [Related]
18. Dopaminergic agonists administered into the nucleus accumbens: effects on extracellular glutamate and on locomotor activity. Dalia A; Uretsky NJ; Wallace LJ Brain Res; 1998 Mar; 788(1-2):111-7. PubMed ID: 9554973 [TBL] [Abstract][Full Text] [Related]
19. Effects of dopaminergic drugs on innate pheromone-mediated reward in female mice: a new case of dopamine-independent "liking.". Agustín-Pavón C; Martínez-Ricós J; Martínez-García F; Lanuza E Behav Neurosci; 2007 Oct; 121(5):920-32. PubMed ID: 17907824 [TBL] [Abstract][Full Text] [Related]
20. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. Hess EJ; Albers LJ; Le H; Creese I J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]